News
RDY
15.26
-0.33%
-0.05
Weekly Report: what happened at RDY last week (0106-0110)?
Weekly Report · 1d ago
Dr. Reddy’s Faces GST Tax Demand, Evaluates Appeal
TipRanks · 4d ago
Dr. Reddy’s to Announce Q3FY25 Financial Results on January 23, 2025
TipRanks · 6d ago
Dr. Reddy’s Sells Non-Strategic Louisiana Subsidiary
TipRanks · 6d ago
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
NASDAQ · 01/07 14:50
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
Benzinga · 01/06 15:40
Weekly Report: what happened at RDY last week (1230-0103)?
Weekly Report · 01/06 09:06
Top ranked Indian equities according to SA Quant
Seeking Alpha · 12/31/2024 16:56
BUZZ-India's Lupin hits record high after buying Eli Lilly's diabetes drug
Reuters · 12/31/2024 06:37
Weekly Report: what happened at RDY last week (1223-1227)?
Weekly Report · 12/30/2024 09:05
Dr. Reddy’s Laboratories’ Credit Rating Reaffirmed by ICRA
TipRanks · 12/27/2024 17:57
Dr. Reddy’s Laboratories Announces Board Meeting for Financial Results Review
TipRanks · 12/23/2024 18:59
Dr. Reddy’s Laboratories Expands European Footprint with New Finnish Subsidiary
TipRanks · 12/23/2024 18:59
Dr. Reddy's Laboratories Forms New Subsidiary In Finland, 'Dr. Reddy's Finland Oy', As Step-Down Wholly-Owned Entity
Benzinga · 12/23/2024 14:24
Weekly Report: what happened at RDY last week (1216-1220)?
Weekly Report · 12/23/2024 09:05
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Benzinga · 12/22/2024 14:51
Dr. Reddy’s Laboratories Allocates Equity Shares to Employees
TipRanks · 12/20/2024 12:15
Impax Global Social Leaders Fund Q3 2024 Commentary
Seeking Alpha · 12/20/2024 10:55
Impax Global Opportunities Fund Q3 2024 Commentary
Seeking Alpha · 12/19/2024 15:30
Dr. Reddy’s downgraded to Neutral from Buy at Nomura
TipRanks · 12/19/2024 10:00
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.